@article{a49b3bd9bbd7423cb836b8fe9c297523,
title = "Cancer fitness genes: emerging therapeutic targets for metastasis",
abstract = "Development of cancer therapeutics has traditionally focused on targeting driver oncogenes. Such an approach is limited by toxicity to normal tissues and treatment resistance. A class of {\textquoteleft}cancer fitness genes{\textquoteright} with crucial roles in metastasis have been identified. Elevated or altered activities of these genes do not directly cause cancer; instead, they relieve the stresses that tumor cells encounter and help them adapt to a changing microenvironment, thus facilitating tumor progression and metastasis. Importantly, as normal cells do not experience high levels of stress under physiological conditions, targeting cancer fitness genes is less likely to cause toxicity to noncancerous tissues. Here, we summarize the key features and function of cancer fitness genes and discuss their therapeutic potential.",
keywords = "cancer fitness genes, cancer therapy, metastasis, stress",
author = "Minhong Shen and Yibin Kang",
note = "Funding Information: The work in the authors{\textquoteright} laboratory is supported by Ludwig Cancer Research, Brewster Foundation, and grants from the American Cancer Society, Susan G. Komen Foundation, Breast Cancer Research Foundation, METAvivor, Department of Defense, and the National Cancer Institute. We apologize to the authors of multiple interesting studies that were not cited here owing to space limitations. Y.K. is a co-founder and chair of scientific advisory board of Firebrand Therapeutics Inc. and is also a co-founder of Kayothera, Inc. and a member of Scientific Advisory Board for Cytocare, Inc. and Vibrant Pharma Limited. M.S. declares no competing interests. Funding Information: The work in the authors{\textquoteright} laboratory is supported by Ludwig Cancer Research , Brewster Foundation , and grants from the American Cancer Society , Susan G. Komen Foundation, Breast Cancer Research Foundation , METAvivor , Department of Defense, and the National Cancer Institute . We apologize to the authors of multiple interesting studies that were not cited here owing to space limitations. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2023",
month = jan,
doi = "10.1016/j.trecan.2022.08.007",
language = "English (US)",
volume = "9",
pages = "69--82",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "1",
}